Something Different

Brilliant 5-minute video explainer of the AMR problem!

 Dear All, Andrew Jack of the Financial Times (FT) has produced a superb 5-minute video explainer of the AMR challenge! Featuring cameos from Kevin Outterson (CARB-X), Christine Ardal (Norwegian Institute of Public Health), and Manica Balasegaram (GARDP), the video deftly illustrates the economic challenge, the way that delinked Netflix-like models provide a solution, and the

Read More »

AMR Action Fund ($1b for P2-3): Video chat with new CEO! New committed funds!

Dear All, I’ve written before about the AMR Action Fund (9 Jul 2020 newsletter): In brief, it is ~$1b pledged by over 20 leading pharmaceutical companies to support the Phase 2-3 studies needed to bring 2-4 new antibiotics to approval by 2030 Stated differently, the AMR Action Fund provides Push incentives for Phase 2-3 to complement the Push Incentives

Read More »

FDA-NIAID phage workshop / Social distancing in the 1800s

Dear All, This webinar merits a standalone newsletter! If you are thinking (or working on) phage, then please mark your calendar for an FDA (CBER; Center for Biologics Evaluation and Research) workshop entitled: Science and Regulation of Bacteriophage Therapy: August 30, 2021—September 1, 2021 The purpose of the public workshop is to exchange information with the

Read More »

Where’s the innovation? / Indian Priority Pathogen List / DTR video explainer

Dear All, Three things briefly this evening: First, the observation about the limited degree of innovation across products in Phases 1-3 in the recent newsletter about the Pew Pipeline review (only 1 in 4 are novel classes or novel mechanisms; none are potentially active against Gram-negative ESKAPE pathogens or WHO critical threat pathogens) generated queries along

Read More »

WHO 2020 clinical/preclinical pipeline review; Chat with WHO’s Peter Beyer

Dear All, WHO have today updated their 2019 clinical/preclinical pipeline review by releasing their 2020 analyses of both the clinical and pre-clinical antibacterial product pipelines (the new 2020 report, the press release). Their 2020 review of antibacterial products in Phase 1 and beyond covers both traditional (n = 43) and non-traditional products (n = 27)

Read More »

CC4CARB solicitation is out (16 Mar 2020 deadline) / Superb WSJ podcast on antibiotic economics

Dear All, I wrote on 3 Jan 2020 (link) about the NIAID contract intended to establish an innovative Chemistry Center for Combating Antibiotic-Resistant Bacteria (CC4CARB). The formal solicitation has now gone live and can be found here. The deadline for applications is 16 Mar 2020. Get to it! In parallel, there is a superb Wall Street Journal podcast dated 13 Jan 2020 about

Read More »

Useful AMR graphics: Poirel 2017 and Marston 2016

Dear All: There’s a very comprehensive review of the polymyxins by Poirel, Jayol, and Nordmann just out in Clin Micro Reviews (https://journals.asm.org/doi/10.1128/CMR.00064-16). If you’re a fan of good quality graphics as way to tell the story of AMR, their Figure 4 is worth capturing! Ditto their Figure 5 of outbreaks of colistin-resistant, carbapenemase-producing K. pneumoniae.

Read More »

PBS FRONTLINE: Hunting the Nightmare Bacteria

Dear All:  Frontline will today broadcast an updated version of the excellent Hunting the Nightmare Bacteria show that first broadcast in 2013. Here’s the link to the announcement and here is the short description of this 1-h program: “Described by the Centers for Disease Control and Prevention as “nightmare bacteria,” there are now predictions that drug-resistant superbugs will kill more

Read More »

Superb PBS Newshour segment on agricultural use of antibiotics + McKeena’s Big Chicken book

Dear All:  I wrote a few weeks ago about the Stopping Superbugs series from PBS Newshour. PBS has since then added some superb new materials: A marvelous 10-minute video story on agricultural use of antibiotics A column on Maryn McKenna’s upcoming Big Chicken book (scheduled for release on 12 Sep) A column on the never-ending debate about taking the entire course of antibiotics These build on

Read More »
Scroll to Top